AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
166 hedge funds and large institutions have $524M invested in AMAG Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 69 increasing their positions, 51 reducing their positions, and 37 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 51
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10.96% less ownership
Funds ownership: 125.88% → 114.92% (-11%)
13% less funds holding
Funds holding: 190 → 166 (-24)
23% less capital invested
Capital invested by funds: $679M → $524M (-$155M)
32% less call options, than puts
Call options by funds: $2.13M | Put options by funds: $3.12M
62% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$21.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.93M |
| 3 |
Renaissance Technologies
New York
|
+$4.35M |
| 4 |
SIM
Spark Investment Management
New York
|
+$3.75M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$42.7M |
| 2 |
JP Morgan Chase
New York
|
-$12.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.1M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$7.19M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.69M |
AMAG Hedge Fund Activity: Q1 2019 in Review
166 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q1 2019, worth a combined $524M — down 23% from $679M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of AMAG and 14 opened new positions — a net loss of 23 holders — while 51 trimmed existing stakes and 69 added.
The largest buyer was Armistice Capital, adding an estimated $21.4M. The largest seller was Jackson Square Partners, cutting an estimated $42.7M.
- 166 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q1 2019, down from 190 in Q4 2018.
- Funds reported $524M of AMAG Pharmaceuticals stock for Q1 2019, down 23% quarter-over-quarter.
- 14 funds opened new AMAG Pharmaceuticals positions in Q1 2019 and 37 closed out, a net change of -23 holders.
- The largest AMAG Pharmaceuticals buyer in Q1 2019 was Armistice Capital, an estimated $21.4M added.
- The largest AMAG Pharmaceuticals seller in Q1 2019 was Jackson Square Partners, an estimated $42.7M sold.
Based on aggregated 13F filings for Q1 2019.